Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Atara Biotherapeutics

DB:AT2
Snowflake Description

Excellent balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AT2
DB
$441M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Atara Biotherapeutics has significant price volatility in the past 3 months.
AT2 Share Price and Events
7 Day Returns
-2.3%
DB:AT2
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-78.6%
DB:AT2
-13.2%
DE Biotechs
-20.9%
DE Market
AT2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Atara Biotherapeutics (AT2) -2.3% -33.4% -49.5% -78.6% -53.2% -83%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • AT2 underperformed the Biotechs industry which returned -13.2% over the past year.
  • AT2 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
AT2
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Atara Biotherapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Atara Biotherapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Atara Biotherapeutics.

DB:AT2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-12-31) in USD $ 0.83333333333333
Payout Ratio Company Filings (2019-12-31) 0%
Discount Rate (Cost of Equity) See below 5.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AT2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (3.62%))
1.149
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.149 * 5.44%)
5.86%

Discounted Cash Flow Calculation for DB:AT2 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Atara Biotherapeutics is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

DB:AT2 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= $0.83 / (5.86% - -0.39%)
$13.17
DB:AT2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AT2 represents 0.99389x of NasdaqGS:ATRA
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.99389x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 13.34 x 0.99389
€13.25
Value per share (EUR) From above. €13.25
Current discount Discount to share price of €7.48
= -1 x (€7.48 - €13.25) / €13.25
43.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Atara Biotherapeutics is available for.
Intrinsic value
44%
Share price is €7.48 vs Future cash flow value of €13.25
Current Discount Checks
For Atara Biotherapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Atara Biotherapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Atara Biotherapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Atara Biotherapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Atara Biotherapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AT2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-5.67
NasdaqGS:ATRA Share Price ** NasdaqGS (2020-04-03) in USD $7.53
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Atara Biotherapeutics.

DB:AT2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ATRA Share Price ÷ EPS (both in USD)

= 7.53 ÷ -5.67

-1.33x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atara Biotherapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Atara Biotherapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Atara Biotherapeutics's expected growth come at a high price?
Raw Data
DB:AT2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.33x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
17.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Atara Biotherapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Atara Biotherapeutics's assets?
Raw Data
DB:AT2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.12
NasdaqGS:ATRA Share Price * NasdaqGS (2020-04-03) in USD $7.53
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:AT2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ATRA Share Price ÷ Book Value per Share (both in USD)

= 7.53 ÷ 5.12

1.47x

* Primary Listing of Atara Biotherapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atara Biotherapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Atara Biotherapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Atara Biotherapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Atara Biotherapeutics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Atara Biotherapeutics expected to grow at an attractive rate?
  • Unable to compare Atara Biotherapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Atara Biotherapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Atara Biotherapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:AT2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:AT2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 17.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AT2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AT2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 318 57 -52 4
2023-12-31 154 -31 -181 5
2022-12-31 53 -145 -289 6
2021-12-31 3 -292 -359 6
2020-12-31 0 -276 -340 8
2020-04-06
DB:AT2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -236 -291
2019-09-30 -234 -292
2019-06-30 -230 -279
2019-03-31 -215 -256
2018-12-31 -180 -231
2018-09-30 -147 -186
2018-06-30 -119 -159
2018-03-31 -100 -135
2017-12-31 -88 -119
2017-09-30 -84 -102
2017-06-30 -79 -97
2017-03-31 -70 -88

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Atara Biotherapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Atara Biotherapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AT2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Atara Biotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AT2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.50 1.15 -2.15 3.00
2023-12-31 -1.80 0.00 -3.45 3.00
2022-12-31 -3.08 -1.87 -4.40 3.00
2021-12-31 -4.56 -3.60 -6.03 5.00
2020-12-31 -5.42 -4.81 -6.30 5.00
2020-04-06
DB:AT2 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -5.67
2019-09-30 -6.05
2019-06-30 -6.07
2019-03-31 -5.62
2018-12-31 -5.27
2018-09-30 -4.65
2018-06-30 -4.37
2018-03-31 -4.16
2017-12-31 -4.00
2017-09-30 -3.48
2017-06-30 -3.33
2017-03-31 -3.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Atara Biotherapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Atara Biotherapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Atara Biotherapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Atara Biotherapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Atara Biotherapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Atara Biotherapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Atara Biotherapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Atara Biotherapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Atara Biotherapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Atara Biotherapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AT2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -290.98 79.58 216.10
2019-09-30 -292.49 81.09 216.71
2019-06-30 -278.96 78.93 206.53
2019-03-31 -255.51 74.89 187.67
2018-12-31 -230.70 69.65 154.96
2018-09-30 -186.00 61.12 129.97
2018-06-30 -158.74 55.32 107.22
2018-03-31 -135.28 45.70 92.13
2017-12-31 -119.49 40.33 81.21
2017-09-30 -102.41 34.58 69.91
2017-06-30 -96.69 30.65 68.11
2017-03-31 -88.14 27.53 62.81
2016-12-31 -79.05 24.73 56.51
2016-09-30 -82.06 24.99 59.27
2016-06-30 -68.56 21.99 48.58
2016-03-31 -64.62 19.10 47.10
2015-12-31 -57.22 16.83 41.62
2015-09-30 -46.50 16.84 30.44
2015-06-30 -40.55 14.40 26.56
2015-03-31 -30.12 12.16 18.23
2014-12-31 -28.01 12.71 15.45
2014-09-30 -21.04 8.33 12.65
2014-06-30 -17.65 7.49 10.09
2014-03-31 -14.52 6.92 7.49
2013-12-31 -8.77 3.76 4.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Atara Biotherapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Atara Biotherapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Atara Biotherapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Atara Biotherapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Atara Biotherapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Atara Biotherapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Atara Biotherapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Atara Biotherapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Atara Biotherapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Atara Biotherapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Atara Biotherapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Atara Biotherapeutics Company Filings, last reported 3 months ago.

DB:AT2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 290.78 0.00 259.11
2019-09-30 318.44 0.00 282.92
2019-06-30 232.28 0.00 190.14
2019-03-31 283.93 0.00 237.55
2018-12-31 338.86 0.00 309.63
2018-09-30 403.05 0.00 364.54
2018-06-30 452.50 0.00 417.02
2018-03-31 439.18 10.30 407.32
2017-12-31 177.86 0.00 166.10
2017-09-30 205.96 0.00 200.22
2017-06-30 221.14 0.00 216.90
2017-03-31 233.13 0.00 230.65
2016-12-31 253.74 0.00 255.68
2016-09-30 270.20 0.00 278.15
2016-06-30 290.25 0.00 294.56
2016-03-31 303.83 0.00 306.40
2015-12-31 315.10 0.00 320.48
2015-09-30 333.75 0.00 334.27
2015-06-30 149.26 0.00 155.03
2015-03-31 166.09 0.00 166.70
2014-12-31 103.18 0.00 104.12
2014-09-30 51.54 0.00 51.70
2014-06-30 56.22 0.00 56.50
2014-03-31 59.87 0.00 62.03
2013-12-31 50.07 0.00 51.62
  • Atara Biotherapeutics has no debt.
  • Atara Biotherapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Atara Biotherapeutics has sufficient cash runway for 1.1 years based on current free cash flow.
  • Atara Biotherapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 45.9% each year.
X
Financial health checks
We assess Atara Biotherapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Atara Biotherapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Atara Biotherapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Atara Biotherapeutics dividends. Estimated to be 11.07% next year.
If you bought €2,000 of Atara Biotherapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Atara Biotherapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Atara Biotherapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AT2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AT2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 1.00 2.00
2021-12-31 1.00 2.00
2020-12-31 0.50 2.00
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Atara Biotherapeutics has not reported any payouts.
  • Unable to verify if Atara Biotherapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Atara Biotherapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Atara Biotherapeutics has not reported any payouts.
Future Payout to shareholders
  • The company is expected to pay a dividend in 3 years whilst incurring a loss, therefore the dividend is not expected to be well covered.
X
Income/ dividend checks
We assess Atara Biotherapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Atara Biotherapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Atara Biotherapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Atara Biotherapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Pascal Touchon
AGE 55
TENURE AS CEO 0.8 years
CEO Bio

Mr. Pascal Touchon has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 2019. He serves as Director of Cogen Therapeutics, Inc. since August 2018. He serves as Global Head of Oncology Strategy & Business Development at Novartis Oncology. Mr. Touchon is responsible for the development & execution of strategy, portfolio management, BD&L, external collaborations and alliance management. Mr. Touchon was previously Senior Executive Vice President and Head of Business Development and Licensing for Servier, a private research-based pharmaceutical company, where he led the sourcing, evaluation, negotiation and closing numerous partnerships with biotechs, pharmaceutical companies and academic institutes. He has held positions in Research, Marketing and Sales, General Management and Business Development at various companies including Sanofi, Virbac, Glaxo, Glaxo-Wellcome and Servier. He has extensive international experience in managing marketing and commercial operations and as managing director in France, Central & Eastern Europe, Northern Europe, Asia, Australia, Canada and South Africa. Educational Background Mr. Touchon holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a Diplôme d'Etudes Supérieures Spécialisées (DESS) in Management from Institut d’Administration des Entreprises (Toulouse, France) and an MBA from INSEAD (Fontainebleau, France).

CEO Compensation
  • Insufficient data for Pascal to compare compensation growth.
  • Insufficient data for Pascal to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Atara Biotherapeutics management team in years:

1.7
Average Tenure
49
Average Age
  • The average tenure for the Atara Biotherapeutics management team is less than 2 years, this suggests a new team.
Management Team

Utpal Koppikar

TITLE
Senior VP & CFO
COMPENSATION
$4M
AGE
49
TENURE
1.8 yrs

Joe Newell

TITLE
Executive VP & Chief Technical Operations Officer
COMPENSATION
$2M
AGE
49
TENURE
3 yrs

Mina Kim

TITLE
Consultant
COMPENSATION
$3M
AGE
45
TENURE
0.4 yrs

Pascal Touchon

TITLE
President
AGE
55
TENURE
0.8 yrs

John Craighead

TITLE
Vice President of Investor Relations & Corporate Communications

Kerry Daly

TITLE
Head of Corporate Communications

Steve Bertram

TITLE
Senior Vice President of Global Human Resources
TENURE
3.7 yrs

AJ Joshi

TITLE
Senior VP & Chief Medical Officer

José Vidal

TITLE
Senior Vice President of Quality Assurance & Process Sciences
TENURE
1.7 yrs

Renu Vaish

TITLE
Senior Vice President of Global Regulatory Affairs
AGE
52
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the Atara Biotherapeutics board of directors in years:

4.8
Average Tenure
55
Average Age
  • The tenure for the Atara Biotherapeutics board of directors is about average.
Board of Directors

Carol Gallagher

TITLE
Chairman & Lead Independent Director
COMPENSATION
$269K
AGE
54

Pascal Touchon

TITLE
President
AGE
55
TENURE
0.8 yrs

Beth Seidenberg

TITLE
Independent Director
COMPENSATION
$247K
AGE
62
TENURE
7.7 yrs

Matt Fust

TITLE
Independent Director
COMPENSATION
$262K
AGE
54
TENURE
6.1 yrs

Eric Dobmeier

TITLE
Independent Director
COMPENSATION
$260K
AGE
50
TENURE
5.1 yrs

Bill Heiden

TITLE
Independent Director
COMPENSATION
$247K
AGE
59
TENURE
4.4 yrs

Roy Baynes

TITLE
Independent Director
COMPENSATION
$411K
AGE
64
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
30. Sep 19 Sell Joseph Newell Individual 27. Sep 19 27. Sep 19 -3,500 €12.34 €-43,190
01. Jul 19 Buy Eric Dobmeier Individual 27. Jun 19 27. Jun 19 2,000 €17.16 €34,312
X
Management checks
We assess Atara Biotherapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Atara Biotherapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.

Details
Name: Atara Biotherapeutics, Inc.
AT2
Exchange: DB
Founded: 2012
$408,803,471
58,571,550
Website: http://www.atarabio.com
Address: Atara Biotherapeutics, Inc.
611 Gateway Boulevard,
Suite 900,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ATRA Common Stock Nasdaq Global Select US USD 17. Oct 2014
DB AT2 Common Stock Deutsche Boerse AG DE EUR 17. Oct 2014
LSE 0HIY Common Stock London Stock Exchange GB USD 17. Oct 2014
BRSE AT2 Common Stock Berne Stock Exchange CH CHF 17. Oct 2014
Number of employees
Current staff
Staff numbers
393
Atara Biotherapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 02:19
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.